新元素医药(江苏新元素医药科技有限公司)是一家成立于2012年、处在临床研发阶段的生物医药公司。新元素医药正在开发Best-in-Class的口服小分子药物,用于治疗炎症和代谢性疾病,如慢性痛风和非酒精性脂肪性肝炎(NASH),这些疾病目前没有有效的治疗方法。

新元素医药用于治疗慢性痛风的药物ABP-671比现有药物更有效,毒性极大减小,并有望在2022年进入全球3期试验。另一个药物ABP-6016在临床前试验中证明了其安全性和有效性,用于治疗NASH这个可能为全球最常见的肝脏疾病。

新元素医药的最新消息

Arthritis & Rheumatology: Study Compares Gout Treatments with Different Mechanisms of Action - URAT1 Inhibitor vs Xanthine Oxidase Inhibitor
Arthritis & Rheumatology:Study Compares Gout Treatments with Different Mechanisms of Action – URAT1 Inhibitor vs Xanthine Oxidase Inhibitor
Healthline: How Gout Flare-ups May Increase the Risk of Heart Attack, Stroke
How Gout Flare-ups May Increase the Risk of Heart Attack, Stroke Gout is a type of arthritis caused by...
Physicians Weekly: Urate-Lowering Treatments Compared for Gout
Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia
PRESS RELEASE Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College...